Monday, July 18, 2016

Recognizing Drug Diversion in Health Care Facilities

Drug diversion is a growing concern in healthcare facilities. Diversion occurs wherever controlled substances are stored or handled. The signs of diversion are often subtle and many healthcare providers believe that people they know could never divert. Recognizing the signs of diversion is crucial to preventing diversion and protecting patients from harm when they are denied needed analgesia or cared for by impaired providers. 

To learn more about visit and download a pamphlet describing the signs of drug diversion in healthcare facilities. 

If you have an upcoming training or would like a guest speaker to present on injection safety, please contact Alana Cilwick (303.692.2727) or Injection Safety Coordinator at CDPHE.

HHA IDR Committee Meeting

The HHA IDR Committee will be not meet on 7/18/16. No IDR requests have been received for this month's meeting. 

If you have any questions, please contact Elaine Sabyan at 303.692.2815 or

Health Advisory – Clinicians Advised Not to Use Liquid Docusate Products in Any Patients

This Health Alert Network (HAN) is an update to a HAN sent out on June 24, 2016.

CDC is currently performing a multi-state investigation into clusters of Burkholderia cepacia among patients in intensive care units. CDPHE and other state health departments are assisting CDC in this investigation.

Preliminary information indicates that a contaminated liquid docusate product might be related to cases. CDC is continuing to investigate. The recommendation by CDC to avoid using any liquid docusate products has been expanded to include all patient populations. Providers should not give any patients liquid docusate products.

Facilities that identify B. cepacia complex infections in non-cystic fibrosis patients or clusters of B. cepacia complex infections in non-cystic fibrosis patients should sequester all liquid docusate products.

CDPHE continues to request facilities report the following:
- Any clusters of B. cepacia or other Burkholderia species identified since January 2016;
- Any cases of B. cepacia or other Burkholderia species in non-cystic fibrosis patients identified since January 2016.

Please notify the Communicable Disease Branch at CDPHE by contacting Geoff Brousseau at 303-692-2766

Applications are being accepted for the Qualified Medication Administration Program (QMAP) Stakeholder Task Force

In response to the passage of House Bill 16-1424 regarding Qualified Medication Administration Personnel (QMAP), the Health Facilities and Emergency Medical Services Division of the department will be convening a QMAP Stakeholder Task Force. 

The objective of this group will be to review existing regulation governing the qualification of unlicensed professionals administering medication in designated facility types in the State of Colorado and make any revision recommendations to both the department and the State Board of Health.

Per Division policy, QMAP Stakeholder Task Force members serve on a voluntary basis and are appointed by the Health Facilities and Emergency Medical Services Division Director. This task force will represent providers and consumers of Qualified Medication Administration training and/or services in residential or day programs, or organizations providing service to or concerned with residents in these settings. Membership will be selected/comprised of:

- 3 Representatives of the Colorado Assisted Living Residence Associations (1 each) 
- 3 Assisted Living Residence or Adult Day Provider Representatives
- 2 QMAP Instructors
- 1 Practicing QMAP

Six task force meetings are to be scheduled once a month, for two hours, with the first meeting scheduled for August 24, 2016. Meeting frequency and duration may be adjusted to meet project timelines.

Applications for current vacancies and considerations will be accepted through August 5, 2016. The announcement, application form and instructions on how to apply can be accessed through the following internet link: